Filing Flows › Comparisons › PRGO vs UTHR
Perrigo vs United Therapeutics: PRGO and UTHR compared
Perrigo is the larger company: $989M of revenue in its latest quarter (Q3 2026) against $832M for United Therapeutics (Q3 2026). United Therapeutics is growing faster (+4% against -5% a year earlier). United Therapeutics is more profitable, with an operating margin of 37.0% against 2.3%.
Where the money goes: PRGO and UTHR
Perrigo (PRGO) · Q3 2026
Perrigo, Q3 2026: revenue $989M (-5% year over year), operating margin 2.3%, net loss $27.5M, operating cash flow $96.2M. The chart follows the revenue to costs, profit and cash.
United Therapeutics (UTHR) · Q3 2026
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
| Perrigo (PRGO) | United Therapeutics (UTHR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $989M | $832M |
| Revenue growth, Y/Y | -5% | +4% |
| Gross margin | — | 88.1% |
| Operating margin | 2.3% | 37.0% |
| Net earnings | −$27.5M | $259M |
| Net margin | -2.8% | 31.1% |
| Operating cash flow | $96.2M | $306M |
| Free cash flow | $78.7M | $126M |
| Market value | $2.2B | $25.5B |
| P/E | — | 21.2× |
| Analysts’ mean target | $18.00 | $670.93 |
Where the revenue comes from
United Therapeutics
- Total Tyvaso: $504M (61%)
- Orenitram: $145M (17%)
- Remodulin: $122M (15%)
- Unituxin: $52.3M (6%)
Questions
Which is bigger, Perrigo or United Therapeutics?
Perrigo is the larger company: $989M of revenue in its latest quarter (Q3 2026) against $832M for United Therapeutics (Q3 2026).
Is Perrigo or United Therapeutics growing faster?
United Therapeutics is growing faster (+4% against -5% a year earlier).
Which is more profitable, Perrigo or United Therapeutics?
United Therapeutics is more profitable, with an operating margin of 37.0% against 2.3%.
More: Perrigo earnings · how Perrigo makes money · United Therapeutics earnings · how United Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.